Cancer Biotech, 2 Others Score IPOs Totaling $279M
Cancer-focused biotechnology firm Turning Point Therapeutics made its public debut Wednesday, recording the most lucrative initial public offering of three companies that brought in a combined $279 million....To view the full article, register now.
Already a subscriber? Click here to view full article